Evidence map›Paper›PMID 33854571›Full record

ArticleTherapeutic advances in musculoskeletal disease2021

Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis.

Alfredo Madrid-García, Inés Pérez, José Ignacio Colomer, Leticia León-Mateos, Juan A Jover, Benjamín Fernández-Gutiérrez, Lydia Abásolo-Alcazar, Luis Rodríguez-Rodríguez

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alfredo Madrid-GarcíaRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.ORCID https://orcid.org/0000-0002-1591-0467
Inés PérezRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
José Ignacio ColomerRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
Leticia León-MateosRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
Juan A JoverRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.ORCID https://orcid.org/0000-0002-6126-8786
Benjamín Fernández-GutiérrezRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
Lydia Abásolo-AlcazarRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
Luis Rodríguez-RodríguezRheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, c\ Prof. Martin Lagos s/n, Madrid, 28040, Spain.ORCID https://orcid.org/0000-0002-2869-7861
Hospital Clínico San Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo analyze the association between colchicine prescription and COVID-19-related hospital admissions in patients with rheumatic and musculoskeletal diseases (RMDs).

methodsPatients attending a rheumatology outpatient clinic from a tertiary care center in Madrid, Spain, from 1 September 2019 to 29 February 2020 were included. Patients were assigned as exposed or unexposed based on whether they were prescribed with colchicine in their last visit to the clinic during the 6 months before the start of the observation period. Treatment changes during the observation period were also considered. The primary outcome was COVID-19-related hospital admissions between 1 March and 20 May 2020. Secondary outcome included COVID-19-related mortality. Several weighting techniques for data balancing, based and non-based on the propensity score, followed by Cox regressions were performed to estimate the association of colchicine prescription on both outcomes. DISCUSSION: The number of patients entered in the study was 9379, with 406 and 9002 exposed and unexposed follow-up periods, respectively. Generalized Boosted Models (GBMs) and Empirical Balancing Calibration Weighting (EBCW) methods showed the best balance for COVID-19-related hospital admissions. Colchicine prescription did not show a statistically significant association after covariable balancing (

conclusionColchicine prescription does not play a significant protective or risk role in RMD patients regarding COVID-19-related hospital admissions. Our observations could support the maintenance of colchicine prescription in those patients already being treated, as it is not associated with a worse prognosis. PLAIN LANGUAGE TITLE: Colchicine influence in COVID-19-related hospital admissions.

Indexed as

colchicineCOVID-19hospital admissionsurvival analysisweighting techniques

Identifiers

PMID33854571
PMCPMC8010810
OpenAlexW3149884120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.